Kontafarma China Holdings (HKSE:01312) ROCE % : -11.33% (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Kontafarma China Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kontafarma China Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -11.33%.

Kontafarma China Holdings ROCE % Historical Data

The historical data trend for Kontafarma China Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kontafarma China Holdings ROCE % Chart

Kontafarma China Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

4.47

1.44

-1.11

-5.44

-1.94

Kontafarma China Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															6.26	-6.51	-4.36	6.58	-11.33

Kontafarma China Holdings ROCE % Calculation

Kontafarma China Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-28.669	/	( ( (2120.443 - 504.707)	+	(1727.335 - 383.6) )	/ 2 )
	=	-28.669	/	( (1615.736	+	1343.735)	/ 2 )
	=	-28.669	/	1479.7355
	=	-1.94 %

Kontafarma China Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-158.138	/	( ( (1827.373 - 378.525)	+	(1727.335 - 383.6) )	/ 2 )
	=	-158.138	/	( ( 1448.848	+	1343.735 )	/ 2 )
	=	-158.138	/	1396.2915
	=	-11.33 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Kontafarma China Holdings (HKSE:01312) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kontafarma China Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Kontafarma China Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kontafarma China Holdings (HKSE:01312) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kontafarma China Holdings Ltd (HKSE:01312) » Definitions » ROCE %

Traded in Other Exchanges

N/A

Address

30 Harbour Road, Room 12A 09-20, 12th Floor, Sun Hung Kai Centre, Wanchai, Hong Kong, HKG

Website

https://www.kontafarma.com.hk

Kontafarma China Holdings Ltd is principally engaged in the manufacture and sale of prescription drugs including chemical drugs and traditional Chinese medicine in the PRC, and the operation of fitness centers, provision of fitness and health consulting services, and the operation of franchises. The operating segments include pharmaceutical business and Fitness business. Majority of its revenue derives from pharmaceutical business segment.

Kontafarma China Holdings (HKSE:01312) Headlines

No Headlines